je.st
news
Tag: with
Competition Bureau steps up probe into Loblaw's dealings with suppliers
2014-11-18 16:06:06| Grocery - Topix.net
Canada's Competition Bureau has subpoenaed several food and beverage suppliers of Loblaw Companies Ltd. in an ongoing investigation into pricing practices following its takeover of Shoppers Drug Mart.
Tags: with
steps
competition
bureau
Vodafone in talks to bundle BSkyB's Now TV with fixed broadband
2014-11-18 01:00:00| Total Telecom industry news
U.K. telco giant reportedly aiming to get a headstart in content by reselling Sky's broadband TV box.
Tags: with
fixed
talks
broadband
CDC: 172 people on cruise fell ill with norovirus
2014-11-17 06:29:01| Biotech - Topix.net
A cruise ship docked in California on Sunday after 172 people on board fell ill with the highly contagious norovirus during a nearly monthlong trip, the Centers for Disease Control and Prevention said. A cruise ship docked in California on Sunday after 172 people on board fell ill with the highly contagious norovirus during a nearly monthlong trip, the Centers for Disease Control and Prevention said.
CDC: 172 people on cruise fell ill with norovirus
2014-11-17 06:29:00| Biotech - Topix.net
In this Oct. 11, 2014 photo, Princess Cruises' Crown Princess leaves the harbor at San Pedro in Los Angeles, bound for a short cruise. The Centers for Disease Control and Prevention says that 172 people on the Crown Princess arriving in California on Sunday, Nov. 16, 2014 have fallen ill with the highly contagious norovirus during a nearly monthlong trip.
MSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
2014-11-16 10:25:00| Merck.com - Research & Development News
Dateline City: ZURICH Pembrolizumab Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed pembrolizumab, the companys anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab- Language: English Contact: MSDMedia:Lainie Keller, +1-908-236-5036Claire Mulhearn, +1-908-236-1118orInvestor:Joseph Romanelli, +1-908-423-5185Justin Holko, +1-908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
study
positive
Sites : [560] [561] [562] [563] [564] [565] [566] [567] [568] [569] [570] [571] [572] [573] [574] [575] [576] [577] [578] [579] next »